Article Text

Download PDFPDF
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors The manuscript has been written by both authors. No professional or additional help has been sought or obtained.

  • Competing interests GD: Vertex, Abbott, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pharmasett, Pfizer, Roche/Genentech, Merck, Tibotec, Astek, Achillion, Janssen: Advisory Board; Bristol Myers, Gilead Sciences, Human Genome Sciences, Presidio: Advisory board/Safety Monitoring Board; Zymogenetics: Safety Monitoring Board.

  • Provenance and peer review Commissioned; internally peer reviewed.